The label for Metformin Hydrochloride Extended Release received a significant update on 2025-03-26 with the addition of a Boxed Warning. This warning highlights the serious risk of lactic acidosis associated with metformin, noting postmarketing cases that have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, making early recognition challenging.
Background
A Boxed Warning, also known as a black box warning, is the strongest warning that the U.S. Food and Drug Administration (FDA) requires for prescription drug products. It is intended to call attention to serious or life-threatening risks. For Metformin Hydrochloride Extended Release, this warning specifically addresses lactic acidosis. This condition is a rare but serious metabolic complication that can occur due to metformin accumulation, particularly in patients with impaired renal function or other predisposing conditions. The warning underscores the critical need for clinicians to be aware of the potential for this severe adverse event.
What this means
The addition of a Boxed Warning for lactic acidosis to the Metformin Hydrochloride Extended Release label reinforces the importance of careful patient selection and monitoring by healthcare providers. Clinicians should thoroughly assess patients for risk factors such as renal impairment, concomitant use of certain drugs, advanced age, and other conditions that may increase the risk of metformin accumulation. Patients should be educated on the symptoms of lactic acidosis, which include malaise, myalgia, respiratory distress, somnolence, and abdominal distress, and advised to seek immediate medical attention if these occur. This label change serves as a crucial reminder of the potential for severe, sometimes fatal, adverse events associated with metformin use, necessitating vigilance in prescribing and patient management to mitigate these risks.
Source
The information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA) through its DailyMed database. The update to the label for Metformin Hydrochloride Extended Release, specifically concerning the Boxed Warning, became effective on 2025-03-26 and is accessible via dailymed.nlm.nih.gov.